Paul Mattels

Stock Analyst at Stifel

(n/a)
# 4,770
Out of 4,789 analysts
4
Total ratings
n/a
Success rate
-37.52%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Paul Mattels

Denali Therapeutics
Dec 16, 2024
Upgrades: Buy
Price Target: $37
Current: $12.29
Upside: +201.06%
Alector
Feb 19, 2020
Initiates: Buy
Price Target: $44
Current: $1.16
Upside: +3,693.10%